user Admin_Adham
7th Oct, 2026 12:00 AM
Test

WHO Endorses Lifestyle Changes Over GLP-1 Drugs in Child Obesity Fight

Oct 7 (Reuters) - The World Health Organization on Wednesday recommended diet, exercise and counseling over popular weight-loss drugs in ⁠its first global guidelines addressing rising obesity among younger children.

According to UNICEF data, obesity has surpassed being underweight as the most common ⁠form of malnutrition in school children and adolescents worldwide.

The health agency said weight-loss drugs may be considered for ⁠adolescents aged 10 to 19 with obesity ‌but only after supervised interventions have failed. Bariatric surgery could be considered for physically and mentally mature adolescents with severe obesity after six months of unsuccessful treatment, it said.

For children under 10, WHO endorsed diet, physical activity and combined behavioral support instead of obesity medication, surgery or devices because of ‌doubts over their safety and long-term effectiveness.

Article Key Points
  • WHO favors diet, exercise, counseling for pediatric obesity.
  • GLP-1s may be considered age 10-19 only after supervised failure.
  • Bariatric surgery: severe obesity, physically/mentally mature adolescents, after 6 months failed treatment.
  • <10 years: no obesity meds, surgery, or devices; safety/efficacy uncertain.
  • Obesity in ages 5-19 quadrupled since 1990; 170M affected in 2024.
Dive Deeper
What predicts response to lifestyle therapy in pediatric obesity?
How safe are GLP-1s in adolescents with obesity?
Which adolescents benefit most from bariatric surgery?

Luz María De Regil, director of the Department ​of Nutrition ‌and Food Safety, said there is currently insufficient ‌evidence on GLP-1 drugs, though researchers are monitoring efficacy and safety trials and may revise that assessment as more data ⁠emerges.

SUGGESTED FOR YOU

"The foundation of obesity care for children and adolescents is ‌not medicine or surgery, but ⁠access to comprehensive support that enables ​healthy eating, physical activity and sustainable behaviour ‌change," De Regil said.

Some GLP-1 medicines are already approved for weight-loss in younger patients. Novo Nordisk's Wegovy and Saxenda can be used by certain adolescents 12 and older in the United States and ​the European Union. The EU also allows Saxenda for some ‌children ‌aged six to 11.

For children and adolescents with obesity, WHO strongly suggested tailored diets, physical activity and ‌behavioral programs involving caregivers, with ​supervised digital support cited as optional.

Healthy diets and physical activity must also be accessible and affordable because treatment alone cannot halt rising obesity, WHO said.

About 400 million people aged ⁠5 to 19 were overweight in 2024, including 170 million living with obesity, ‌WHO said. Obesity prevalence in the group has quadrupled since 1990.

(Reporting by Kunal Das and ​Christy Santhosh in Bengaluru; Editing by Pooja Desai)

Dive Deeper
Commonly Asked by HCPs


Share This Article

Comments

Leave a comment